References
Uncategorized References
1. Cohen-Cymberknoh M, Shoseyov D, Kerem E. Managing cystic fibrosis: Strategies that increase life expectancy and improve quality of life.American Journal of Respiratory and Critical Care Medicine.2011;183(11):1463-1471.
2. Sturgess JM. Structural and developmental abnormalities of the exocrine pancreas in cystic fibrosis. J Pediatr Gastroenterol Nutr. 1984;3 Suppl 1:S55-66.
3. Pencharz PB, Durie PR. Pathogenesis of malnutrition in cystic fibrosis, and its treatment. Clinical Nutrition.2000;19(6):387-394.
4. Scott RB, O’Loughlin EV, Gall DG. Gastroesophageal reflux in patients with cystic fibrosis. The Journal of Pediatrics.1985;106(2):223-227.
5. Vaisman N, Pencharz PB, Corey M, Canny GJ, Hahn E. Energy expenditure of patients with cystic fibrosis. J Pediatr. 1987;111(4):496-500.
6. Calella P, Valerio G, Brodlie M, Donini LM, Siervo M. Cystic fibrosis, body composition, and health outcomes: a systematic review.Nutrition. 2018;55-56:131-139.
7. Corey M, McLaughlin FJ, Williams M, Levison H. A comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto. Journal of Clinical Epidemiology.1988;41(6):583-591.
8. Kastner-Cole D, Palmer CNA, Ogston SA, Mehta A, Mukhopadhyay S. Overweight and Obesity in ΔF508 Homozygous Cystic Fibrosis. The Journal of Pediatrics. 2005;147(3):402-404.
9. Grey AB, Ames RW, Matthews RD, Reid IR. Bone mineral density and body composition in adult patients with cystic fibrosis. Thorax.1993;48(6):589.
10. Stallings VA, Stark LJ, Robinson KA, Feranchak AP, Quinton H. Evidence-Based Practice Recommendations for Nutrition-Related Management of Children and Adults with Cystic Fibrosis and Pancreatic Insufficiency: Results of a Systematic Review. Journal of the American Dietetic Association. 2008;108(5):832-839.
11. Sullivan JS, Mascarenhas MR. Nutrition: Prevention and management of nutritional failure in Cystic Fibrosis. J Cyst Fibros. 2017;16 Suppl 2:S87-s93.
12. Egan ME. Cystic fibrosis transmembrane conductance receptor modulator therapy in cystic fibrosis, an update. Curr Opin Pediatr. 2020;32(3):384-388.
13. Bailey J, Rozga M, McDonald CM, et al. Effect of CFTR Modulators on Anthropometric Parameters in Individuals with Cystic Fibrosis: An Evidence Analysis Center Systematic Review. J Acad Nutr Diet.2020.
14. Hanna RM, Weiner DJ. Overweight and obesity in patients with cystic fibrosis: A center-based analysis. Pediatric Pulmonology.2015;50(1):35-41.
15. Gelfond D, Heltshe S, Ma C, et al. Impact of CFTR Modulation on Intestinal pH, Motility, and Clinical Outcomes in Patients With Cystic Fibrosis and the G551D Mutation. Clinical and Translational Gastroenterology. 2017;8(3).
16. Edgeworth D, Keating D, Ellis M, et al. Improvement in exercise duration, lung function and well-being in G551D-cystic fibrosis patients: A double-blind, placebo-controlled, randomized, cross-over study with ivacaftor treatment. Clinical Science.2017;131(15):2037-2045.
17. Stallings VA, Sainath N, Oberle M, Bertolaso C, Schall JI. Energy Balance and Mechanisms of Weight Gain with Ivacaftor Treatment of Cystic Fibrosis Gating Mutations. Journal of Pediatrics.2018;201:229-237.e224.
18. https://www.cdc.gov/healthyweight/bmi/calculator.html.
19. http://gli-calculator.ersnet.org/
20. Cystic Fibrosis Foundation Patient Registry 2020 Annual Data Report. Cystic Fibrosis Foundation;2021.
Table 1. General characteristics of study participants